NCT03350815 · Interventional trial
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
Overall registry status Completed
Phase 4
Conditions Ankylosing Spondylitis
Delaware Valley sites
- Novartis Investigative Site · Voorhees Township, NJ · Camden County
First posted
Registry updated
Added to the directory